On October 25, 2022 Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, reported that preclinical data from the Company’s asset NMS-03602173 will be reported in a poster presentation by Dr. Paola Magnaghi at the upcoming EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2022) which will be held October 26-28, 2022 at the CCIB in Barcelona (Press release, Nerviano Medical Sciences, OCT 25, 2022, View Source [SID1234623260]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the upcoming presentation are as follows:
About NMS-03602173 (NMS-173)
NMS-173 is a second generation potent, covalent, selective, and orally available investigational new drug for the treatment of cancer patients with mutated IDH1 or IDH2. IDH1 and IDH2 mutations confer to these enzymes a neomorphic activity promoting the conversion of α-KG into 2-HG, an oncometabolite that induces a global epigenetic rewiring, leading to de-differentiation, stemness and tumorigenesis. NMS-173 potently inhibits mutant IDH1 and IDH2 thus resulting in the abrogation of 2-HG production in a variety of cells and in a number of in vivo mouse models including IDH mutant cholangiocarcinoma, glioma and AML models, with significant tumor growth inhibition and anti-tumor efficacy superior to FDA approved first generation inhibitors. Due to its covalent MOA, NMS-173 has high potential of sustained clinical responses compared to FDA approved drugs and can also potentially overcome resistance mechanisms to first generation IDH inhibitors. Notably, NMS-173 has received authorization to start phase I clinical studies in US and Europe in patients with IDH1 or IDH2 mutated solid tumors including low grade glioma.